Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo

Nicole D. Vincelette, Husheng Ding, Amelia M. Huehls, Karen S. Flatten, Rebecca L. Kelly, Mira A. Kohorst, Jonathan Webster, Allan D. Hess, Keith W. Pratz, Larry M Karnitz, Scott H Kaufmann

Research output: Contribution to journalArticle

Abstract

CPX-351 is a liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regulatory approval for the treatment of therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes based on improved overall survival compared to standard cytarabine/daunorubicin therapy. Checkpoint kinase 1 (CHK1), which is activated by DNA damage and replication stress, diminishes sensitivity to cytarabine and anthracyclines as single agents, suggesting that CHK1 inhibitors might increase the effectiveness of CPX-351. The present studies show that CPX-351 activates CHK1 as well as the S and G2/M cell cycle checkpoints. Conversely, CHK1 inhibition diminishes the cell cycle effects of CPX-351. Moreover, CHK1 knockdown or addition of a CHK1 inhibitor such as MK-8776, rabusertib or prexasertib enhances CPX-351-induced apoptosis in multiple TP53-null and TP53-wildtype AML cell lines. Likewise, CHK1 inhibition increases the antiproliferative effect of CPX-351 on primary AML specimens ex vivo, offering the possibility that CPX-351 may be well suited to combine with CHK1-targeted agents.

Original languageEnglish (US)
Article number3617
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Acute Myeloid Leukemia
Cytarabine
Daunorubicin
G2 Phase Cell Cycle Checkpoints
In Vitro Techniques
Checkpoint Kinase 1
Anthracyclines
Myeloid Cells
DNA Replication
DNA Damage
Cell Cycle
Apoptosis
Cell Line
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Vincelette, N. D., Ding, H., Huehls, A. M., Flatten, K. S., Kelly, R. L., Kohorst, M. A., ... Kaufmann, S. H. (2019). Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Scientific reports, 9(1), [3617]. https://doi.org/10.1038/s41598-019-40218-0

Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. / Vincelette, Nicole D.; Ding, Husheng; Huehls, Amelia M.; Flatten, Karen S.; Kelly, Rebecca L.; Kohorst, Mira A.; Webster, Jonathan; Hess, Allan D.; Pratz, Keith W.; Karnitz, Larry M; Kaufmann, Scott H.

In: Scientific reports, Vol. 9, No. 1, 3617, 01.12.2019.

Research output: Contribution to journalArticle

Vincelette, ND, Ding, H, Huehls, AM, Flatten, KS, Kelly, RL, Kohorst, MA, Webster, J, Hess, AD, Pratz, KW, Karnitz, LM & Kaufmann, SH 2019, 'Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo', Scientific reports, vol. 9, no. 1, 3617. https://doi.org/10.1038/s41598-019-40218-0
Vincelette ND, Ding H, Huehls AM, Flatten KS, Kelly RL, Kohorst MA et al. Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Scientific reports. 2019 Dec 1;9(1). 3617. https://doi.org/10.1038/s41598-019-40218-0
Vincelette, Nicole D. ; Ding, Husheng ; Huehls, Amelia M. ; Flatten, Karen S. ; Kelly, Rebecca L. ; Kohorst, Mira A. ; Webster, Jonathan ; Hess, Allan D. ; Pratz, Keith W. ; Karnitz, Larry M ; Kaufmann, Scott H. / Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{de7cb7bd21904a669ae51a19665bbbdb,
title = "Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo",
abstract = "CPX-351 is a liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regulatory approval for the treatment of therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes based on improved overall survival compared to standard cytarabine/daunorubicin therapy. Checkpoint kinase 1 (CHK1), which is activated by DNA damage and replication stress, diminishes sensitivity to cytarabine and anthracyclines as single agents, suggesting that CHK1 inhibitors might increase the effectiveness of CPX-351. The present studies show that CPX-351 activates CHK1 as well as the S and G2/M cell cycle checkpoints. Conversely, CHK1 inhibition diminishes the cell cycle effects of CPX-351. Moreover, CHK1 knockdown or addition of a CHK1 inhibitor such as MK-8776, rabusertib or prexasertib enhances CPX-351-induced apoptosis in multiple TP53-null and TP53-wildtype AML cell lines. Likewise, CHK1 inhibition increases the antiproliferative effect of CPX-351 on primary AML specimens ex vivo, offering the possibility that CPX-351 may be well suited to combine with CHK1-targeted agents.",
author = "Vincelette, {Nicole D.} and Husheng Ding and Huehls, {Amelia M.} and Flatten, {Karen S.} and Kelly, {Rebecca L.} and Kohorst, {Mira A.} and Jonathan Webster and Hess, {Allan D.} and Pratz, {Keith W.} and Karnitz, {Larry M} and Kaufmann, {Scott H}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-40218-0",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo

AU - Vincelette, Nicole D.

AU - Ding, Husheng

AU - Huehls, Amelia M.

AU - Flatten, Karen S.

AU - Kelly, Rebecca L.

AU - Kohorst, Mira A.

AU - Webster, Jonathan

AU - Hess, Allan D.

AU - Pratz, Keith W.

AU - Karnitz, Larry M

AU - Kaufmann, Scott H

PY - 2019/12/1

Y1 - 2019/12/1

N2 - CPX-351 is a liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regulatory approval for the treatment of therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes based on improved overall survival compared to standard cytarabine/daunorubicin therapy. Checkpoint kinase 1 (CHK1), which is activated by DNA damage and replication stress, diminishes sensitivity to cytarabine and anthracyclines as single agents, suggesting that CHK1 inhibitors might increase the effectiveness of CPX-351. The present studies show that CPX-351 activates CHK1 as well as the S and G2/M cell cycle checkpoints. Conversely, CHK1 inhibition diminishes the cell cycle effects of CPX-351. Moreover, CHK1 knockdown or addition of a CHK1 inhibitor such as MK-8776, rabusertib or prexasertib enhances CPX-351-induced apoptosis in multiple TP53-null and TP53-wildtype AML cell lines. Likewise, CHK1 inhibition increases the antiproliferative effect of CPX-351 on primary AML specimens ex vivo, offering the possibility that CPX-351 may be well suited to combine with CHK1-targeted agents.

AB - CPX-351 is a liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regulatory approval for the treatment of therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes based on improved overall survival compared to standard cytarabine/daunorubicin therapy. Checkpoint kinase 1 (CHK1), which is activated by DNA damage and replication stress, diminishes sensitivity to cytarabine and anthracyclines as single agents, suggesting that CHK1 inhibitors might increase the effectiveness of CPX-351. The present studies show that CPX-351 activates CHK1 as well as the S and G2/M cell cycle checkpoints. Conversely, CHK1 inhibition diminishes the cell cycle effects of CPX-351. Moreover, CHK1 knockdown or addition of a CHK1 inhibitor such as MK-8776, rabusertib or prexasertib enhances CPX-351-induced apoptosis in multiple TP53-null and TP53-wildtype AML cell lines. Likewise, CHK1 inhibition increases the antiproliferative effect of CPX-351 on primary AML specimens ex vivo, offering the possibility that CPX-351 may be well suited to combine with CHK1-targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=85062586128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062586128&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-40218-0

DO - 10.1038/s41598-019-40218-0

M3 - Article

C2 - 30837643

AN - SCOPUS:85062586128

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 3617

ER -